Finance

Lists
Q3 2026 earnings • released • EPS beat +0.99% • Revenue beat +1.13%
See results
ZBH:NYSE
Zimmer Biomet Holdings, Inc
$109.18
-0.88%
(-0.97) 1D
Nov 5, 11:05:50 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBH...
Open
$111.00
High
$111.21
Low
$109.06
Mkt. cap
20.91B
Avg. vol.
2.21M
Volume
501.76K
Dividend
0.88%
Quarterly dividend
$0.24
Ex-dividend date
Sep 30, 2026
P/E ratio
26.69
52-wk high
$112.54
52-wk low
$79.12
EPS
$4.11
Beta
0.50
Shares outstanding
190.74M
No. of employees
17K
Open
$111.00
High
$111.21
Low
$109.06
Mkt. cap
20.91B
Avg. vol.
2.21M
Volume
501.76K
Dividend
0.88%
Quarterly dividend
$0.24
Ex-dividend date
Sep 30, 2026
P/E ratio
26.69
52-wk high
$112.54
52-wk low
$79.12
EPS
$4.11
Beta
0.50
Shares outstanding
190.74M
No. of employees
17K
News stories
From web sources and news partners
Profile
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster. In 2001, Zimmer was spun off from Bristol Myers Squibb and began trading on the New York Stock Exchange, on August 7, under the ticker symbol “ZMH”. In November 2011, the company acquired ExtraOrtho, Inc. In January 2012, the company acquired Reno, Nevada-based Synvasive Technology, Inc. On June 29, 2015, the company changed the ticker symbol to "ZBH" to reflect its acquisition of Biomet. On January 12, 2017, Zimmer Biomet announced a resolution with the DOJ and the SEC in which it agreed to pay a fine of approximately $30.5 million, an amount which would not affect its 2017 outlook. Wikipedia
About Zimmer Biomet Holdings, Inc
CEOIvan Tornos
Employees17K
Founded1927
HeadquartersWarsaw, Indiana, United States
SectorMedical device
Industry-
Websitezimmerbiomet.com
Analyst ratings
Based on 18 analysts giving stock ratings to ZBH in the past 3 months
Hold
Buy
4
Hold
14
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for ZBH in the last 3 months.
Highest
Current $109.18
$130.00 (+19.06%)
Average
$112.50 (+3.04%)
Lowest
$97.00 (-11.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robbie Marcus
J.P. Morgan
Hold
Maintained
$120.00
+9.9%
11/05/2026
Patrick Wood
UBS
Buy
Reiterated
$130.00
+19.1%
11/05/2026
Vik Chopra
BMO Capital
Hold
Reiterated
$102.00
-6.6%
11/04/2026
Caitlin Cronin
Canaccord Genuity
Hold
Maintained
$111.00
+1.7%
11/05/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$125.00
+14.5%
11/05/2026
Larry Biegelsen
Wells Fargo
Hold
Reiterated
$113.00
+3.5%
11/05/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
11/04/2026
Joanne Wuensch
Citi
Hold
Maintained
$117.00
+7.2%
11/05/2026
Jeff Johnson
Robert W. Baird
Hold
Maintained
$114.00
+4.4%
11/05/2026
Lee Hambright
Bernstein
Hold
Reiterated
$107.00
-2%
11/05/2026
Christopher Pasquale
Barclays
Hold
Maintained
$100.00
-8.4%
11/05/2026
Kendall Au
RBC Capital
Buy
Reiterated
$125.00
+14.5%
11/04/2026
David Toung
Argus Research
Buy
Reiterated
$125.00
+14.5%
10/21/2026
Mike Kratky
Leerink Partners
Hold
Reiterated
$97.00
-11.2%
10/12/2026
Gray Powell
BTIG
Hold
Maintained
-
-
10/09/2026
Matt Miksic
Barclays
Hold
Maintained
$100.00
-8.4%
10/07/2026
Travis Steed
Bank of America Securities
Hold
Maintained
$110.00
+0.7%
09/25/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$106.00
-2.9%
09/16/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
$100.00
-8.4%
08/10/2026
Pito Chickering
Deutsche Bank
Hold
Maintained
$98.00
-10.2%
08/06/2026
Steven Lichtman
William Blair
Hold
Maintained
-
-
08/06/2026
Michael Matson
Needham
Hold
Maintained
-
-
08/05/2026
Mathew Blackman
TD Cowen
Buy
Maintained
$115.00
+5.3%
08/05/2026
Danielle Antalffy
UBS
Buy
Upgraded
$115.00
+5.3%
07/28/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$101.00
-7.5%
07/13/2026
Unknown Analyst
BMO Capital
Hold
Initiated
$95.00
-13%
07/09/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$110.00
+0.7%
07/06/2026
David Turkaly
Citizens JMP
Buy
Maintained
$105.00
-3.8%
04/29/2026
David Roman
Goldman Sachs
Sell
Maintained
$88.00
-19.4%
02/10/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$1.90 / $1.88
+0.99%beat
Revenue / Est. (USD)
2.06B / 2.04B
+1.13%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.00B
2.24B
2.09B
2.18B
Cost of goods sold
559.30M
795.50M
594.20M
635.50M
Cost of revenue
559.30M
795.50M
594.20M
635.50M
Research and development expenses
115.90M
118.70M
103.40M
104.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
809.40M
838.50M
846.20M
882.30M
Operating expense
1.10B
1.13B
1.11B
1.15B
Total operating expenses
1.66B
1.93B
1.71B
1.79B
Operating income
340.30M
313.40M
380.80M
391.00M
Other non operating income
6.20M
15.10M
5.50M
6.00M
EBT including unusual items
279.20M
97.90M
301.30M
255.10M
EBT excluding unusual items
269.30M
250.00M
310.20M
320.80M
Income tax expense
48.00M
-39.90M
63.00M
55.50M
Effective tax rate
17.19%
-40.76%
20.91%
21.76%
Other operating expenses
-
-
-
-
Net income
230.90M
139.30M
238.10M
198.30M
Net profit margin
11.54%
6.21%
11.41%
9.11%
Earnings per share
1.90
2.42
2.09
2.07
Interest and investment income
-
-
-
-
Interest expense
-75.40M
-71.90M
-68.80M
-72.90M
Net interest expenses
-75.40M
-71.90M
-68.80M
-72.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
623.90M
597.40M
650.80M
661.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps